Unknown
PHASE2
INTERVENTIONAL
NCT05005715
Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
In multiple previous studies that have explored the use of dexmedetomidine in transsphenoidal tumor resection surgery, dexmedetomidine showed many beneficial effects like reducing the requirement of analgesics and anesthetics, improving hemodynamic stability and decreasing the emergence time, extubation time and visual analog scale at emergence. Therefore, the investigators hypothesized that dexmedetomidine would decrease neuroendocrine stress response and improve the quality of postoperative recovery.
Interventions
Name:
Dexmedetomidine
Type:
DRUG
Description:
Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
Name:
normal saline
Type:
DRUG
Description:
Patients were randomly assigned to the dexmedetomidine or control group. Dexmedetomidine group received intravenous dexmedetomidine and control group received intravenous normal saline during surgery.
Primary Outcomes
Measure:
Quality of recovery-15 (QoR-15) score
TimeFrame:
postoperative day 1
Description:
Self-rated questionnaire composed of 15 items (each item: 0-10 points, total: 0-150 points) of five dimensions: physical well-being, physical independence, emotional state, psychological support, and pain. Higher scores indicate better quality of recovery.
Trial Information
NCT ID
NCT05005715
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Seoul National University Hospital
Last Updated
December 15, 2025